Imunon, Inc. (IMNN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMNN SEC filings page.
This page shows Imunon, Inc. (IMNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage economics remain dominant: lower operating costs have not removed Imunon's roughly $14.7M annual cash requirement.
In FY2025, the operating loss was$14.7M versus operating cash flow of-$13.9M , showing losses were largely cash-consuming rather than depreciation-driven. R&D and SG&A together were$14.6M , nearly the entire operating loss; paired with the reported positive net-income result despite negative EPS, this points to development spending—not noncash charges—as the central operating mechanic.
Operating losses narrowed from
Debt-to-equity declined from 1.3x in FY2024 to 0.7x in FY2025. The current ratio rose from 1.7x to 2.3x, alongside financing cash flow of
Financial Health Signals
Imunon, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Imunon, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Imunon, Inc. used $0.96 of operating cash (-$13.9M OCF vs $14.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Imunon, Inc.'s EBITDA was -$2.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.1% from the same quarter a year earlier. Against the prior quarter it is up 35.8%.
Imunon, Inc. reported -$2.8M in net income in Q2 2026. This represents a decrease of 2.7% from the same quarter a year earlier. Against the prior quarter it is up 33.8%.
Imunon, Inc. earned -$0.54 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 35.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
Imunon, Inc. held $6.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Imunon, Inc.'s ROE was -67.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 35.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 59.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Imunon, Inc. invested $1.5M in research and development in Q2 2026. This represents an increase of 19.4% from the same quarter a year earlier. Against the prior quarter it is down 37.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
IMNN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.5M+19.4% | $2.3M+8.0% | N/A | $1.9M-42.3% | $1.2M-56.5% | $2.2M-34.3% | N/A | $3.3M+66.3% |
| SG&A Expenses | $1.3M-13.9% | $2.0M-0.6% | N/A | $1.6M-5.5% | $1.5M-29.8% | $2.0M+15.3% | N/A | $1.7M-13.3% |
| Operating Income | -$2.8M-0.9% | -$4.3M-3.9% | N/A | -$3.5M+29.9% | -$2.8M+44.8% | -$4.1M+17.3% | N/A | -$5.0M-27.1% |
| EBITDA | -$2.7M-1.1% | -$4.2M-3.9% | N/A | -$3.4M+30.6% | -$2.7M+45.5% | -$4.1M+17.5% | N/A | -$4.9M-27.7% |
| Interest Expense | $77K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.8M-2.7% | -$4.2M-3.6% | N/A | -$3.4M+29.2% | -$2.7M+42.8% | -$4.1M+16.8% | N/A | -$4.8M-39.4% |
| EPS (Basic) | -$0.54+74.9% | -$0.84+73.3% | -$1.30-465.2% | -$1.16+69.1% | -$2.15+71.9% | -$3.15-505.8% | -$0.23+55.8% | -$3.76-916.2% |
| EPS (Diluted) | -$0.54 | -$0.84 | -$1.30 | -$1.16 | -$2.15 | -$3.15 | -$0.23+55.8% | -$3.76 |
| Diluted Shares (Avg) | 5M | 5M | N/A | 3M | 1M | 1M | N/A | 1M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
IMNN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.0M+70.6% | $8.0M+16.9% | $12.3M+26.5% | $9.0M-37.5% | $8.8M-9.3% | $6.9M-52.1% | $9.7M-55.7% | $14.4M-41.6% |
| Current Assets | $8.7M+26.1% | $6.6M+30.0% | $10.7M+33.9% | $7.3M-42.1% | $6.9M-9.9% | $5.1M-57.9% | $8.0M-56.1% | $12.5M-42.3% |
| Cash & Equivalents | $6.9M+45.2% | $4.8M+66.9% | $8.8M+49.5% | $5.3M-49.1% | $4.7M-10.9% | $2.9M+22.4% | $5.9M+0.6% | $10.3M-20.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% |
| Accounts Receivable | N/A | N/A | $0 | N/A | N/A | N/A | $0 | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.8M+76.2% | $4.7M-27.3% | $5.2M-4.5% | $4.9M-20.9% | $6.1M+3.0% | $6.4M+10.0% | $5.5M-35.8% | $6.2M-5.8% |
| Current Liabilities | $4.8M-10.1% | $4.2M-28.1% | $4.6M-3.4% | $4.2M-22.9% | $5.3M+4.7% | $5.8M+20.3% | $4.8M-35.2% | $5.4M+2.4% |
| Non-Current Liabilities | $6.0M+642.3% | $493K-19.6% | $602K-12.3% | $708K-6.5% | $811K-7.1% | $613K-39.2% | $687K-39.7% | $758K-40.2% |
| Total Equity | $4.2M+57.5% | $3.4M+643.2% | $7.1M+66.4% | $4.1M-50.2% | $2.7M-28.9% | $452K-94.7% | $4.2M-68.3% | $8.2M-54.7% |
| Retained Earnings | -$428.4M-3.6% | -$425.5M-3.6% | -$421.3M-3.6% | -$417.1M-3.6% | -$413.6M-4.0% | -$410.9M-4.5% | -$406.8M-4.8% | -$402.7M-5.1% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
IMNN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.0M-2.5% | -$4.0M-40.0% | -$3.7M+17.3% | -$4.4M-9.5% | -$3.0M+34.5% | -$2.8M+51.5% | -$4.4M-17.2% | -$4.1M+9.3% |
| Depreciation & Amortization | $70K-6.7% | $70K+5.0% | $75K | $75K+16.8% | $75K+9.8% | $67K-5.1% | N/A | $64K-5.5% |
| Stock-Based Compensation | N/A | $549K+168.2% | N/A | N/A | N/A | $205K+766.7% | N/A | N/A |
| Capital Expenditures | N/A | N/A | $4K-75.9% | $0-100.0% | $17K | $260K+2108.9% | $15K | $3K-98.8% |
| Free Cash Flow | N/A | N/A | -$3.7M+17.5% | -$4.4M-9.4% | -$3.0M+34.1% | -$3.1M+47.2% | -$4.4M-17.6% | -$4.1M+13.9% |
| Investing Cash Flow | N/A | N/A | -$4K+75.9% | $0+100.0% | -$17K-100.2% | -$260K-110.9% | -$15K+99.5% | -$3K-100.0% |
| Financing Cash Flow | $10.2M+110.6% | -$2K-101.7% | $7.2M+219533.0% | $5.0M | $4.8M | $106K | -$3K-110.8% | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IMNN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -67.2%+35.9pp | -126.5%+781.1pp | N/A | -84.0%-24.9pp | -103.0%+25.0pp | -907.6%-849.6pp | N/A | -59.2%-39.9pp |
| Return on Assets | -18.8%+12.4pp | -53.0%+6.8pp | N/A | -38.1%-4.5pp | -31.2%+18.2pp | -59.8%-25.4pp | N/A | -33.7%-19.6pp |
| Current Ratio | 1.82+0.5x | 1.59+0.7x | 2.32+0.6x | 1.73-0.6x | 1.30-0.2x | 0.88-1.6x | 1.67-0.8x | 2.30-1.8x |
| Debt-to-Equity | 2.58+0.3x | 1.39-12.8x | 0.74-0.5x | 1.20+0.4x | 2.30+0.7x | 14.18+13.5x | 1.29+0.7x | 0.76+0.4x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Imunon, Inc. IMNN | FY2025 | N/A | $14.5M | N/A | $7.2M | — |
| Briacell Therapeutics Corp. BCTX | FY2025 | N/A | -$26.3M | N/A | $35.1M | — |
| NextCure, Inc. NXTC | FY2025 | N/A | -$55.8M | N/A | $23.3M | — |
| BioVie, Inc. BIVI | FY2026 | N/A | -$22.1M | N/A | $12.7M | — |
| CARISMA THERAPEUTICS INC CARM | FY2024 | $19.6M | -$60.5M | N/A | $6.4M | — |
| Portage Biotech Inc. PRTG | FY2018 | N/A | $123.7M | N/A | $15.5M | — |
Where Imunon, Inc. Ranks
Frequently Asked Questions
Is Imunon, Inc. profitable?
Yes, Imunon, Inc. (IMNN) reported a net income of $14.5M in fiscal year 2025.
What is Imunon, Inc.'s EBITDA?
Imunon, Inc. (IMNN) had EBITDA of -$14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Imunon, Inc.'s return on equity (ROE)?
Imunon, Inc. (IMNN) has a return on equity of 205.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Imunon, Inc.'s free cash flow?
Imunon, Inc. (IMNN) recorded an outflow of $14.2M in free cash flow during fiscal year 2025. This represents a 24.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Imunon, Inc.'s operating cash flow?
Imunon, Inc. (IMNN) recorded an outflow of $13.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Imunon, Inc.'s total assets?
Imunon, Inc. (IMNN) had $12.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Imunon, Inc.'s capital expenditures?
Imunon, Inc. (IMNN) invested $281K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Imunon, Inc. spend on research and development?
Imunon, Inc. (IMNN) invested $7.8M in research and development during fiscal year 2025.
What is Imunon, Inc.'s current ratio?
Imunon, Inc. (IMNN) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.
What is Imunon, Inc.'s debt-to-equity ratio?
Imunon, Inc. (IMNN) had a debt-to-equity ratio of 0.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Imunon, Inc.'s return on assets (ROA)?
Imunon, Inc. (IMNN) had a return on assets of 118.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Imunon, Inc.'s P/E ratio?
Imunon, Inc. (IMNN) trades at 0.5x earnings, its market capitalization divided by net income of $14.5M net income, FY2025. The market capitalization is $7.2M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Imunon, Inc.'s price-to-sales ratio?
Imunon, Inc. (IMNN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.2M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Imunon, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Imunon, Inc. (IMNN) held $8.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.9M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Imunon, Inc.'s Piotroski F-Score?
Imunon, Inc. (IMNN) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Imunon, Inc.'s earnings high quality?
For every $1 of reported earnings, Imunon, Inc. (IMNN) used $0.96 of operating cash (-$13.9M OCF vs $14.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.